BUZZ — India's Zydus Lifesciences to benefit from Novartis dropping rival ALS drug, says Bernstein
* Zydus Lifesciences to benefit from Novartis discontinuing its drug for neurodegenerative disorder ALS for failing to meet goals in mid-stage study, according to Bernstein analysts * ZYDU's candidate Usnoflast's demonstration of clinically meaningful slowing of disease progression in ongoing Phase II clinical trial to